ENTXHealthcare · BiotechnologyThe 5 Wall Street analysts covering Entera Bio Ltd. hold a median 12-month price target of $9.5 — +197.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Entera Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ENTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +197.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Guggenheim | Initiates | Buy | $11 |
| 25 Sept 2026 | Guggenheim | Initiates | Buy | — |
| 23 Sept 2026 | LifeSci Capital | Initiates | Outperform | $10 |
| 23 Sept 2026 | LifeSci Capital | Initiates | Outperform | — |
| 22 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 22 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | $9.00 |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ENTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Entera Bio Ltd. returned +13.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 1% of US stocks
Cheaper than 4% of US stocks
Cheaper than 93% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Entera Bio Ltd. has a market value of $556.6M and an enterprise value of $543.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.0M.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Trailing P/E: −12.8×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Entera Bio Ltd. employs 20 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Entera Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Entera Bio appointed Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026. He will succeed Haya Taitel, who is stepping down.
Why it matters — ENTX watchers may note the board change and the addition of a clinical leader.
Entera presented post-hoc Phase 2 data at the ASBMR 2026 Annual Meeting showing greater BMD gains and anabolic effects with EB613 among postmenopausal women with osteoporosis (baseline T-scores ≤-2.5) than among those with osteopenia (T-scores >-2.5). The presentation also showcased the Phase 3 design.
Why it matters — The results and Phase 3 design are relevant to ENTX watchers tracking EB613’s clinical development for postmenopausal women with osteoporosis at high risk of fracture.
Entera Bio announced that an additional presentation on the clinical study design for its planned Phase 3 registrational trial of EB613, an oral PTH(1-34) tablet, will be presented at the ASBMR 2026 Annual Meeting, October 9–12 in Boston.
Why it matters — The presentation will provide further information about the design of Entera’s planned Phase 3 study of EB613.
Entera Bio announced that biopharmaceutical executive Laura Hamill will join its Board of Directors, effective December 1, 2026.
Why it matters — The appointment adds a global biopharmaceutical executive to Entera’s board, expanding its commercial expertise.
Entera Bio announced that its CEO, Miranda Toledano, will participate in upcoming fall investor conferences. The announcement was made on August 27, 2026, via GlobeNewsWire and corrects a prior release.
Why it matters — An ENTX watcher would care because the CEO's participation in investor conferences provides the company with opportunities to present its oral peptide development pipeline to the investment community.
The 5 Wall Street analysts covering Entera Bio Ltd. have a median 12-month price target of $9.5, with estimates ranging from $9 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Entera Bio Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entera Bio Ltd. 52 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Entera Bio Ltd. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +197.8% from the last close, and Ticker Nerd's factor model ranks Entera Bio Ltd. 52 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Entera Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $11 over the next 12 months.
Entera Bio Ltd. returned +13.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors". Entera Bio appointed Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026. He will succeed Haya Taitel, who is stepping down.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.
CEO Ms. Miranda J. Toledano M.B.A. · 20 employees · Israel · https://enterabio.com
